TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Volume difference between limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Circulating Lycopene Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood pressure level in the morning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of CD4+ T cells, CD8+ T cells, B cells, monocytes, and dendritic cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of peptide-specific IFN-gamma and IL-5 producing T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number and severity of hematologic and non-hematologic toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic-pharmacodynamic model validation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of IGF indicative of patient outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Myocardial Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With no Residual Tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximal percent decrease in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Identification of tongue features associated with diabetes and pre-diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cerebrovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change Over Time in Selective Reminding Test (SRT) Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: HIV screening uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in conversion of IGT to diabetes
Endpoint domain: Mortality/survival
Primary endpoint: Probability of not suffering a grade 3 or higher toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in IRLS Rating Scale Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Score of Much Improved or Very Much Improved on the CGI-I Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: FSH, LH, E2, P, T, and PRL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ovary volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ovulating period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total scores of abstinence syndrome symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of pre-specified clinical and arrhythmic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Normal tissue effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in serum CRP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline in pocket depth (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline in Clinical Attachment Level (CAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Endoscopic Improvement at Week 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Radioactive Dose Recovered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pneumothorax recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Energy expenditure in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fat oxidation in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Abdominal Site Responder Rates at 10 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Abdominal Site Responder Rates at 6 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Groin Site Responder Rate at 6 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Groin Sites Responder Rates at 10 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Non-serious Treatment-emergent Adverse Events (TEAEs), Serious TEAEs (STEAEs) and Adverse Events of Special Interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage change in wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: PWAT 0-24 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Physical functioning assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Heavy Drinking Days Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With no Heavy Drinking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with complete abortion
Endpoint domain: Mortality/survival
Primary endpoint: Duration of Acute Nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in number of falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Age at all cause death or censoring
Endpoint domain: Mortality/survival
Primary endpoint: Age at death of cardiovascular disease
Endpoint domain: Mortality/survival
Primary endpoint: retrieval rate of cumulus-oocyte complexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mean Value of the Peak VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental Recovery (IR, K Value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Estriol plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Successful IVD implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adverse events (vascular complications)
Endpoint domain: Adverse events/effects
Primary endpoint: appearance and expansion in the circulation of autologous transduced T-lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: improved laboratory measures of immune function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in HAMD-17 total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Glucose blood level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rate of attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Impaired glucose tolerance or diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of change of Urine Albumin-to-Creatinine Ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Vein closure success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ability to diagnose neoplastic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from Baseline Performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety of tgAAC09
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluation of intervention effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average weekly completion rate for Mood check-in
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average weekly completion rate for Anxiety check-in
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average weekly completion rate for online journaling
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants with GI Perforation/Fistula Events by Grade
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with GI-Vaginal Fistula Events by Grade
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with GU Fistula Events by Grade
Endpoint domain: Adverse events/effects
Primary endpoint: Change in low density cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone resorption around dental implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity and tolerability measured by calcium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stroop test score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reinjury
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of individuals shedding vaccine strain viruses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Duration of shedding of vaccine viruses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Accuracy of the timed Timed Up-and-go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of the Bertec BalanceCheck Screener system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to find venous access
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in regional cerebral oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Knee functionality after total knee replacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of correct anti-saccade trials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety assessment before surgery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety assessment after surgery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Willingness to have HIV testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in GLX to Creatine Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in CDRS-R Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent of participants mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Quadriceps Central Activation Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma LDOPS Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma DHMA Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma DHPG Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24 Week Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Quality of recovery 40 (QoR-40) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Weill-Cornell LINCL scale at 18 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in MRI parameters at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evolution registration by photograph
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Musculoskeletal Complains at 2 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Pain Intensity at 2 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Biomechanical Exposure immediately after the interventional training and after two months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 Months Progression Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Descriptive norms about alcohol and sex
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Injunctive norms about alcohol and sex
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Expectancies about alcohol use and sex
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived benefits of protective behavioral strategies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-efficacy to use protective behavioral strategies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Lipid Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Child welfare system recidivism
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Achieving ASAS 20 Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of reported self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in biomarker beclin-1 after Rhythmic Handgrip Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in biomarker Atg3 after Rhythmic Handgrip Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in biomarker Atg5 after Rhythmic Handgrip Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in biomarker Atg7 after Rhythmic Handgrip Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in biomarker Lamp1 after Rhythmic Handgrip Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1c change rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diabetic eye disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Change in Moderate to Vigorous Activity (MVPA) During Recess
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fundamental Motor Skill Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of oral glucose tolerance test (OGTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients experiencing Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Confirmed Objective Response (OR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in craving for a cigarette
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of angiogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of AZD2624
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of asthma and allergy related diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ease of Endotracheal Intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lopinavir Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in diameter (mm) and end diastolic and systolic LV volumes (mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Transmural enhancement (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thickness of the LV wall (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence no reflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Predictive values of CT criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost per patient referred to MRI or Neurology
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Biochemical signs of central nervous system injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Subjective Stress Ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Cortisol Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in Heart-Rate-Variability (HRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Annualised factor consumption (IU)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Telomere Length dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance to Cutaneous Electrical Current
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Any Unprotected Anal Intercourse (UAI) With Casual Partners
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting HIV Testing Behavior
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Reporting Sexually Transmitted Disease (STD) Testing Behavior
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 30 day postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Flusher priming, connection, and activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year treatment success rate
Endpoint domain: Mortality/survival
Primary endpoint: Early Liver Allograft Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of Ceftaroline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants With Disease Activity Score Based on 28-Joints Count (DAS28) Less Than (<) 2.6 at Month 6 and Maintained Till Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Simplified Disease Activity Index (SDAI) Less Than or Equal to (<=) 3.3 at Month 6 and Maintained Till Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Clinical Disease Activity Index (CDAI) <=2.8 at Month 6 and Maintained Till Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of motor tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response time of motor tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in insulin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma AUC of Diclofenamic Acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects achieving Hb ≥ 11.0 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Patients Achieving Blood Pressure Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Coherence between middle cerebral artery blood flow velocity and systemic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with endothelial dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delirium guideline adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patency of metal stent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Endurance Exercise Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score at 48 hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score at 72 hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety as assessed by nature, frequency and severity of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Vital Sign Abnormalities and/or Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Laboratory Value Abnormalities and/or Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Negative predictive value of OSNA technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of p75NTR-ECD total
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of anti-HLA donor-specific antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes